Hi George,
I’ll take stab here at what I believe the issue is here. While some posters may believe Kevetrin will have miraculous results as a single agent, I think the disconnect is when this optimism is expressed in the sense that it will “cure cancer”. I believe it does have the potential to “cure” some of cancer, saying it will “cure cancer” is s broad statement. That said I do believe “K” has the potential to cure some of cancer and it may be in the form as a single agent. I look at Kevetrin as currently being in bottom of the 1st or 2nd inning of a ballgame. The current study does not meet statistical significance when trying to deal with issues of efficacy, however significant important data can be gleaned from the small sample size just the same. Info that will enable Cellceutix to refine future directions in the use of Kevetrin. We certainly cannot conclude Kevetrin cannot be utilized as a single agent in the future from the current study, especially one in which the patients are 4th stage patients who have advanced, refractory disease and who typically have very compromised immune systems and other problems due to the advanced nature of their disease. The current study is not designed to answer what the response might be if “K” was used earlier in the disease process where patients are not as compromised, the tumor burden is less and where they have not developed more refractory disease via more mutations, etc. That is a significant aspect when trying to determine efficacy in a patient population. If used earlier (stage 1 or 2) it may very well meet or exceed current treatment options, we just don’t know. In my opinion future studies will be performed both as a single agent and in combination because P53 mutations are present in so many cancers. In addition, Kevetrin may very well be proven highly effective when conventional treatment has resulted in no detectable disease and oncologists opt to use afterwards to prevent recurrence or extend cancer free status if the patient had P53 mutations in their tumor type to begin with.
In closing much more study is needed before we conclude optimal uses for “K”. I agree 100% that I think it will be highly effective when used in combination but I disagree when you conclude that “K” is unlikely to be utilized as a single agent at this time, more study is needed. I think we should all try to remain open minded, we all want “K” to succeed and I thinks it’s best to not endlessly debate/focus on whether it’s as a single agent or in combination with treatment modalities, we all hope is successful for those who unfortunately are dealing with any form of cancer.
Best to all from sunny Florida.
News 
Market Data 
Discover 
AI
